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Abstract
Background: Mortality estimates alone are not sufficient to understand the true magnitude of
cancer burden. We present the detailed estimates of mortality and incidence by site as the basis
for the future estimation of cancer burden for the Global Burden of Disease 2000 study.
Methods: Age- and sex- specific mortality envelope for all malignancies by region was derived
from the analysis of country life-tables and cause of death. We estimated the site-specific cancer
mortality distributions from vital records and cancer survival model. The regional cancer mortality
by site is estimated by disaggregating the regional cancer mortality envelope based on the mortality
distribution. Estimated incidence-to-mortality rate ratios were used to back calculate the final
cancer incidence estimates by site.
Results: In 2000, cancer accounted for over 7 million deaths (13% of total mortality) and there
were more than 10 million new cancer cases world wide in 2000. More than 60% of cancer deaths
and approximately half of new cases occurred in developing regions. Lung cancer was the most
common cancers in the world, followed by cancers of stomach, liver, colon and rectum, and breast.
There was a significant variations in the distribution of site-specific cancer mortality and incidence
by region.
Conclusions: Despite a regional variation, the most common cancers are potentially preventable.
Cancer burden estimation by taking into account both mortality and morbidity is an essential step
to set research priorities and policy formulation. Also it can used for setting priorities when
combined with data on costs of interventions against cancers.
Background
Mortality estimates alone are not sufficient to understand
the true magnitude and trends of cancer problems and to
evaluate the interventions against cancer, in particular
preventive programmes [1]. Although cancer is still a fatal
disease in many developing countries[2], the disability
among cancer survivors should be taken into account
since there is a growing evidence that cancer survival in
some developing countries are continuously improving
[3,4] and, when setting priorities, cancer control interven-
tions are compared with other health interventions which
aims at reducing morbidity [5]. For this reason, estimates
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of both mortality and incidence of cancer by region are es-
sential inputs for setting research and intervention priori-
ties in cancer control policies.
The present study is aimed at estimating the magnitude of
global and regional cancer mortality and incidence as a
part of detailed analysis of all-cause levels and cause of
death distributions for 191 Member States of the World
Health Organization (WHO) for the Global Burden of
Disease 2000 (GBD 2000) study [6]. GBD 2000 employs
a time-based composite measure of disease burden in
terms of disability-adjusted life years (DALYs) which con-
sist of years lived with disability (morbidity) and years of
life lost (mortality). To estimate the burden from each dis-
ease sequelae, detailed information of incidence, dura-
tion, and mortality by age, sex and region is required [5].
This study serves as a basis for the future estimation of
cancer burden for the GBD 2000.
The GBD 2000 project classified WHO's 6 regions into 17
sub regions according to the levels of child and adult mor-
tality (Table 1). On the basis of available published infor-
mation on age-, sex-, and site-specific cancer incidence
and survival, we developed an algorithm to estimate re-
gion-specific overall cancer mortality, and site-specific
survival, death distributions, and incidence for the year
2000.
In the previous paper, we presented the cancer survival
model as a key input to estimate the distribution of cancer
deaths by site for the regions where mortality data are ei-
ther scarce or unavailable and tested its performance and
validity [7]. In this paper, we present a detailed approach
to estimating mortality and incidence of cancer by site and
the results of mortality and incidence estimation by site
for the year 2000.
Table 1: Global Burden of Disease 2000 (GBD 2000) project: regions and sub regions
WHO region Mortality 
stratum
Sub region WHO Member States
AFRO D AfrD Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Comoros, Equatorial Guinea, 
Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, 
Niger, Nigeria, Sao Tome And Principe, Senegal, Seychelles, Sierra Leone, Togo, Djibouti, Somalia, 
Sudan
AFRO E AfrE Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The 
Congo, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, 
Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe
AMRO A AmrA Canada, United States Of America
AMRO B AmrB Antigua And Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil, Chile, Colombia, Costa Rica, 
Dominica, Dominican Republic, El Salvador, Grenada, Guyana, Honduras, Jamaica, Mexico, Panama, 
Paraguay, Saint Kitts And Nevis, Saint Lucia, Saint Vincent And The Grenadines, Suriname, Trinidad 
And Tobago, Uruguay, Venezuela Cuba
AMRO D AmrD Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, Peru
EMRO B EmrB Bahrain, Cyprus, Iran (Islamic Republic Of), Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Oman, 
Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, United Arab Emirates
EMRO D EmrD Egypt, Iraq, Morocco, Yemen
EURO A EurA Andorra, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, 
Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San 
Marino, Slovenia, Spain, Sweden, Switzerland, United Kingdom
EURO B1 EurB1 Albania, Bosnia And Herzegovina, Bulgaria, Georgia, Poland, Romania, Slovakia, The Former Yugo-
slav Republic Of Macedonia, Turkey, Yugoslavia
EURO B2 EurB2 Armenia, Azerbaijan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan
EURO C EurC Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, 
Ukraine
SEARO B SearB Indonesia, Sri Lanka, Thailand Malaysia, Philippines Brunei Darussalam, Singapore
SEARO D SearD Bangladesh, Bhutan, India, Maldives, Nepal Afghanistan, Pakistan
WPRO A WprA Australia, Japan, New Zealand
WPRO B1 WprB1 China, Mongolia, Republic Of Korea DPR Korea
WPRO B2 WprB2 Cambodia, Lao People's Democratic Republic, Viet Nam Myanmar
WPRO B3 WprB3 Cook Islands, Fiji, Kiribati, Marshall Island s, Micronesia (Federated States Of), Nauru, Niue, Palau, 
Papua New Guinea, Samoa, Solomon Islands, Tonga, Tuvalu, VanuatuBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Material and Methods
Overview of analysis
The Global Burden of Disease 2000 (GBD 2000) study
deals with the problem of systemic bias in cause-specific
mortality by estimating total mortality for each Member
State, starting from an analysis of the overall mortality en-
velope for each region, in order to ensure that the cause-
specific estimates add to the total all cause mortality by
age and sex and that there is not systematic over- or under-
estimation or double counting of deaths. This regional
cause-specific mortality envelope serves as an upper bond
of mortality from a certain cause and partly ensures the in-
ternal consistency among incidence, prevalence and mor-
tality rates [6]. The approaches to estimating mortality
and incidence of cancer by site also follows this process
(Figure 1).
Firstly, we obtained the age- and sex- specific mortality en-
velope for all malignancies by region derived from the
analysis of country life-tables and cause of death models
in each region. Secondly, we estimated the site-specific
cancer mortality distributions from vital records or cancer
survival models depending on the availability and quality
of detailed cause of death data. Cancer sites for which sur-
vival was calculated were: mouth and pharynx (ICD-10
C00-C14), oesophagus (C15), stomach (C16), colon and
rectum (C18-C21), liver (C22), pancreas (C25), trachea,
bronchus and lung (C33-C34), melanoma (C43), female
breast (C50), cervix uterine (C53), corpus uteri (C54-55),
ovary (C56), prostate (C61), bladder (C67), lymphomas
and multiple myeloma (C81-C90, C96), leukaemia (C91-
C95), and other malignant neoplasms (balance of ICD-10
C00-C97). The GBD 2000 assigns Kaposi's sarcoma and
non-Hodgkin lymphomas (NHL) attributable to HIV/
AIDS among AIDS sequela and their burden is included
separately with HIV/AIDS. Thirdly, the final regional can-
cer mortality by site is estimated by disaggregating the re-
gional cancer envelope based on the mortality
distribution by site. Finally, we applied the incidence-to-
mortality rate ratios to back calculate the final cancer inci-
dence estimates by site.
GBD 2000 regional mortality estimates by age, sex, and 
cause
Complete or incomplete vital registration data together
with sample registration systems now cover 74% of global
mortality in 128 countries. Survey data and indirect de-
mographic techniques provide information on levels of
child and adult mortality for the remaining 26% of esti-
mated global mortality. The available sources of mortality
data for the WHO sub regions of the GBD 2000 are sum-
marised in Table 1.
Causes of death for the WHO sub regions and the world
have been estimated based on data from national vital
registration systems that capture about 17 million deaths
annually. In addition, information from sample registra-
tion systems, population laboratories and epidemiologi-
cal analyses of specific conditions have been used to
improve estimates of the cause of death patterns [6,8,9].
As a general rule, vital registration data, suitably corrected
for ill-defined coding and probable systematic biases in
certifying deaths to non-specific vascular, cancer and inju-
ry codes were used to estimate the cause of death pattern.
The GBD 2000 approach adjusts the cause-specific mor-
tality to include a proportion of deaths coded to ill-de-
fined causes in vital registration data and redistributes
these deaths pro-rata among broader communicable and
non-communicable causes.
Cause of death data have been carefully analysed to take
into account incomplete coverage of vital registration in
countries and the likely differences in cause of death pat-
terns that would be expected in the uncovered and often
poorer sub-populations [10]. For countries lacking suffi-
cient vital registration data, cause of death models were
used to firstly estimate the maximum likelihood distribu-
tion of deaths across the broad categories of communica-
ble, non-communicable and injuries, based on estimated
total mortality rates and income [8]. A regional model
pattern of specific causes of death was then constructed
based on local vital registration and verbal autopsy data,
and this proportionate distribution was then applied
within each broad cause group. Finally, the resulting esti-
mates were then adjusted based on other epidemiological
evidence from specific disease studies. Methods used to
estimate global all-cause and cause-specific mortality
from these data are described elsewhere [6].
In the GBD 1990 [5], deaths coded to ICD-9 195–199
(i.e., malignant neoplasm of other and unspecified sites
including those whose point of origin cannot be deter-
mined, secondary and unspecified neoplasm) were redis-
tributed pro-rata across all malignant neoplasm categories
within each age-sex group, so that the category 'Other ma-
lignant neoplasms' includes only malignant neoplasms of
other specified sites. Reviews of the cancer registry and
methods of diagnosis suggest that four sites (month and
pharynx, liver, breast and cervix uteri) where there did not
appear to be any significant mis-coding of cancer deaths,
since these can be diagnosed clinically without any further
diagnostic tests even in developing regions [11]. Accord-
ingly, the cancer garbage code redistribution algorithm
was revised for the GBD 2000 to redistribute cancer deaths
in ICD C76-C80 pro-rata across the sites other than the
four sites above.
Estimation of cancer mortality and incidence
Given the regional cancer mortality envelope by age and
sex, the site-specific distributions of cancer mortality areBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Figure 1
Approaches to estimating global and regional cancer mortality and incidence by site for the Global Burden of Disease 2000 
(GBD 2000)
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necessary to disagreggate the estimated total cancer deaths
by age and sex for each region. The approaches to estimat-
ing mortality distributions were different depending on
the availability and quality of data on detailed causes of
death.
Direct estimates of the site-specific distributions of cancer
mortality were possible for the regions where established
vital registration records with high coverage and ICD-cod-
ing are available, including countries in the A sub regions
(AmrA, EurA and WprA) and countries in AmrB, EurB1,
EurB2 and EurC [6]. For the other regions of the world
(AfrD, AfrE, AmrD, EmrB, EmrD, SearB, SearD, WprB1,
WprB2 and WprB3 sub regions), a site-specific model for
relative interval survival adjusted for each region was de-
veloped and applied to the regional incidence estimated
by International Agency for Research on Cancer (IARC) to
calculate the mortality distribution by site for the year
2000 [7,12]. The region-specific incidence estimates of the
Globocan 2000 was adjusted to ensure the consistency
with the GBD 2000 definitions [7]. Our survival model
and adjusted incidence estimates of the Globocan 2000
were primarily used to estimate the distribution, but not
the magnitude, of cancer by site, sex, and age group.
The final site-specific cancer mortality was then estimated
by multiplying age- and sex- specific regional cancer mor-
tality envelope by estimated cancer mortality distribution
by site. The cancer survival model is flexible enough to
yield the survival estimates of various age, years and peri-
od as well as mean duration of time of cancer by site [7].
We estimated incidence-to-mortality rate ratios at each
age group form the survival model and, by using the final
cancer mortality, applied the ratios to back calculate the fi-
nal incidence by age and sex for each cancer site in all re-
gions of the world for the year 2000.
Results
Cancer mortality by region
The GBD 2000 classifies the cause of deaths into three
broad categories: communicable disease, non-communi-
cable disease, and injuries. In 2000, approximately 56
million deaths occurred world wide and non-communi-
cable disease accounted for 58% of total number of
deaths, followed by communicable disease (33%) and in-
juries (9%) (Figure 2). Cancer was estimated to account
for over 7 million deaths (13% of total mortality and 22%
of non-communicable disease mortality) world wide in
2000, only preceded by cardiovascular diseases (29 % of
total) and infectious and parasitic diseases (19%). De-
pending on the extent of health transition, cancer mortal-
ity as a proportion of total mortality differed substantially
by region, from less than 5% in AfrE to approximately
30% in WprA sub region.
Tables 2,3,4,5 show the regional estimates of total
number of deaths and age-specific mortality rates of all
cancers for the GBD 2000. More than 60% of cancer
deaths occurred in developing regions, particularly in
SearD (mainly India) and WprB1(mainly China) sub re-
gions due to their large population size. On average global
cancer mortality rates among males and females were
128.2 and 104.6 per 100,000, respectively. Not surpris-
ingly crude mortality rates from all cancers vary signifi-
cantly and are much higher in developed regions (AmrA,
EurA, and WprA). However, since age-specific mortality
rate is generally higher in developing regions, regional
mortality rates, age-standardised to the world population,
showed less variations compared to crude mortality rates
and higher mortality rates were observed in regions such
as AfrD, AfrE, AmrB, EurC, and WprB (Figure 3).
Cancer mortality envelope was disaggregated by applying
the distribution of cancer mortality by site estimated from
both the detailed analysis of vital records and the use of
survival model and incidence data from the International
Agency for Research on Cancer (IARC). Tables 6 and 7
show the estimated global and regional numbers of
deaths and age-standardised mortality rates by sex for 17
cancer sites. Generally higher mortality rates were ob-
served in developing regions except cancers of lung and
pancreas which are more prevalent in developed regions
and highly fatal.
Tables 8 and 9 represent the ranking of the number of
deaths by cancer site in the world and three selected sub
regions: a high child and adult mortality/low income re-
gion (AfrE), a very low child and adult mortality/high in-
come region (EurA), and a low child and adult mortality/
middle income region (SearB). Lung cancer was the
leading cause of cancer deaths in the world, accounting
for 17% of total cancer mortality, followed by cancers of
stomach (12% of total), liver (9%), colon and rectum
(9%), and breast (7%). In males, lung, stomach, and liver
cancers were the three most common cause of cancer
deaths. The leading cause of cancer deaths among females
was breast but lung cancer was already the second largest
cause of cancer deaths.
There is a significant variation in the distribution of site-
specific cancer mortality by region. In AfrE, the leading
causes of cancer mortality in males and females were liver
and cervix uteri cancers, respectively, both of which are
primarily due to viral infections. Liver cancer accounted
for approximately one quarter of all male cancer deaths
and cervical cancer accounted for more than one-third of
female cancer deaths. In EurA, the pattern of cancer mor-
tality distribution is a typical one observed in industrial-
ised countries: lung, colorectal, and prostate cancers
accounted for a large proportion of male cancer mortalityBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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while breast, colorectal, and lung cancers were major caus-
es among females. Site-specific cancer mortality
distribution in SearB lay somewhere between the two sub
regions, although lung and breast cancers were already
leading causes of cancer deaths in males and females,
respectively.
Cancer incidence by site
Regional incidence was back calculated from multiplying
mortality by site-specific incidence-to-mortality rate ratios
by age, sex, and region. As shown in Table 10, (age-stand-
ardised) incidence-to-mortality rate ratio was generally
higher in cancers with relatively better prognosis
including lymphoma, leukaemia, and cancers of colon
and rectum, breast, uterus, and ovary. As a result, the new
cases of such cancers as a proportion of total new cases
were higher than the proportion of mortality from same
cancers. Although this pattern was consistent across the
regions, the ratios varied substantially by age, sex, and re-
gion (data not shown).
Tables 11,12,13 show the regional estimates of total new
cases and age-specific incidence rates of all cancers in
2000. More than 10 million new cancers cases occurred
world wide. Due to the differences in survival by region,
estimated incidence-to-mortality rate ratios were generally
much higher in developed regions and the proportion of
cancer incidence in developing regions was approximately
50% of total cancer incidence in the world. Despite their
much smaller population size, the number of new cases in
AmrA and EurA are comparable to those in SearD and
WprB1. On average global cancer incidence rates among
males and females were 169.7 and 171.1 per 100,000, re-
spectively (Figure 4). Regional age-standardised incidence
rates also suggest that female incidence was slightly higher
than male incidence in developing regions, particularly in
Figure 2
Regional distribution of mortality by cause, 2000
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AmrD where the number of deaths female cancers was
high. On the other hand, male and female incidence rates
were almost the same in all A sub regions (AmrA, EurA,
and WprA).
Estimated global and regional numbers of new cases and
age-standardised incidence rates for 17 cancer sites by sex
are shown in Tables 14 and 15. As in mortality distribu-
tion, there is a significant variations in the distribution of
site-specific cancer incidence by region (Tables 16 and
17). The distribution of cancer incidence was almost sim-
ilar to that of mortality: lung cancer was the most com-
mon cancer in the world in 2000, accounting for 13% of
total cancer mortality, followed by cancers of stomach
(10% of total), liver (10%), colon and rectum (10%), and
breast (6%). The variations in the distribution of site-spe-
cific new cases of cancer by region were also similar to
those observed in mortality distribution. In all regions,
compared to proportion of total mortality, the proportion
of lung cancer decreased while that of colon and rectum,
breast, uterus and prostate increased, suggesting the differ-
ence in survival by cancer site as suggested above.
Discussion
Various attempts have been made to quantify the global
burden of cancer and to estimate site-specific cancer mor-
tality and morbidity [1,12–15]. More recently, the efforts
made by the International Agency for Research on Cancer
(IARC) have led to the Globocan 2000 estimates, which
has also used information on incidence and survival to es-
timate cancer death for the year 2000 from various sources
including cancer registries [12,13]. The analyses reported
here have built extensively on the IARC work to synthesis
and estimate cancer mortality and incidence distributions
by site for all regions of the world. Compared to the
estimates of the Globocan 2000, the GBD 2000 estimates
Figure 3
Age-standardised mortality rate from all cancers by region, 2000
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for global cancer mortality and incidence are 11% and 3%
higher, respectively. Although the overall difference in
terms of proportion is small, the absolute difference
between the two estimates remains relatively large. This
difference is predominantly due to a substantially large
difference in the AFRO, EMRO, and SEARO regions.
Some researchers suggest that model-based estimates of
cancer mortality in GBD 1990 bear little relation to the
actual profile of cancer recorded at the regional registries
[1,16]. The proposed approach here is substantially differ-
ent from the previous estimates and, although broader
cause of death to estimate cancer envelope is still based on
cause of death models in some countries, majority of the
data sources of cause of death is now vital registration
and/or sampling data. The total number of mortality from
cancer is not extrapolated by model alone and the survival
model was used to estimate the distribution of death by
site, not the actual magnitude of cancer mortality in re-
gions where no or little data on detailed cause of death is
available. The model estimates were consistent with
mortality distribution of vital records and the Globocan
2000 [7]. Therefore, the major source of discrepancy is not
the estimated cancer mortality distribution but the overall
mortality envelope applied to each region.
The Globocan 2000 estimates are based on either cancer
incidence data from cancer registries in the region (with a
survival model used to estimate deaths) or on mortality
data collected by regional cancer registries or other
sources. Both these sources of data are likely to be incom-
plete and to result in underestimation of cancer deaths.
On the other hand, the GBD 2000 starts with data on the
level of all-cause mortality, and uses all available data on
cause of death and cause of death models where such data
is not available, to estimate the distribution of major
Figure 4
Age-standardised incidence rate from all cancers by region, 2000
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Table 2: Mortality data sources (number of Member States with recent deaths coverage) by WHO sub region for the GBD2000
Subregion Category I: Com-
plete vital statistics 
(95%+ coverage)
Category II: 
Incomplete vital 
statistics
Category III: Sam-
ple registration and 
surveillance systems
Category IV: 
Child mortality esti-
mated from sur-
veys and censuses
Category V: No 
recent data on child 
or adult mortality
Number of 
countries
A f r D 2 2 01 932 6
A f r E 0 2 11 432 0
A m r A 300003
A m r B 1 7 9000 2 6
A m r D 040206
E m r B 43060 1 3
E m r D 020529
E u r A 2 6 0000 2 6
E u r B 79000 1 6
E u r C 810009
S e a r B 110103
S e a r D 012317
W p r A 410005
W p r B 31 21 6 02 2
W o r l d 7 5 4 745 69 1 9 1
Table 3: Estimated global and regional number of total cancer deaths (thousands) and mortality rate (per 100,000) by age, both sexes, 
2000
Region Age-group
0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total
Number of deaths (000s)
World 46.0 49.4 141.3 462.1 1,503.0 1,852.4 1,901.0 1,078.7 7,033.9
AfrD 5.0 2.5 10.7 26.3 59.2 70.0 66.5 31.5 271.6
AfrE 4.9 2.6 15.2 33.1 65.0 76.4 72.1 31.5 300.8
AmrA 0.6 1.2 3.9 23.1 102.4 132.3 194.5 168.1 626.2
AmrB 3.2 4.4 10.7 31.7 86.4 94.3 103.5 66.6 400.8
AmrD 1.0 1.4 2.7 6.4 14.8 16.0 18.9 11.5 72.9
EmrB 1.2 2.0 3.8 8.0 19.2 18.2 17.8 7.7 77.8
EmrD 1.9 2.5 4.3 10.6 17.8 15.1 13.2 4.3 69.7
EurA 0.7 1.5 5.3 31.3 154.1 238.2 350.9 279.8 1,061.7
EurB1 0.7 1.1 3.9 16.6 59.3 76.6 69.8 26.5 254.5
EurB2 0.2 0.6 1.4 4.3 7.9 10.9 7.5 1.9 34.8
EurC 0.8 1.7 5.8 28.4 114.2 162.1 146.1 44.5 503.7
SearB 2.9 4.0 7.9 30.9 90.0 79.8 59.1 25.9 300.6
SearD 12.9 11.9 32.7 65.1 189.0 262.1 192.2 109.2 875.1
WprA 0.2 0.4 1.6 7.7 49.6 77.6 104.2 90.4 331.6
WprB1 8.9 10.6 28.5 128.2 451.6 503.1 467.5 165.6 1,764.0
WprB2 0.9 1.0 3.0 9.5 21.4 18.9 16.7 13.3 84.8
WprB3 0.0 0.1 0.2 0.6 1.2 0.7 0.4 0.2 3.4
Age-specific mortality rate per 100,000
World 7.6 4.1 9.0 36.3 186.8 548.2 965.1 1,702.1 116.5
AfrD 9.1 2.8 11.6 49.5 210.0 667.6 1,386.4 2,799.0 81.4
AfrE 8.5 2.7 16.3 63.6 243.8 798.9 1,612.8 2,932.2 89.1
AmrA 2.9 2.6 6.3 31.5 178.2 581.8 1,074.1 1,901.0 203.1
AmrB 7.0 4.9 8.6 34.1 159.9 463.9 895.3 1,773.8 90.7
AmrD 10.7 8.2 13.3 51.0 211.0 593.4 1,354.4 2,827.8 102.3
EmrB 7.3 5.7 9.1 31.5 144.0 374.6 688.6 1,182.8 55.8
EmrD 10.2 7.5 11.0 41.5 129.5 305.6 540.6 716.3 50.5
EurA 3.2 3.1 6.6 33.1 196.8 570.4 1,109.9 2,089.7 259.6BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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EurB1 5.7 4.2 9.0 47.1 226.3 602.5 874.0 1,325.3 153.5
EurB2 3.7 4.8 10.0 41.5 172.8 450.4 584.6 550.4 68.4
EurC 6.7 5.1 10.4 51.3 266.1 656.0 911.4 1,012.8 205.4
SearB 7.1 5.0 7.0 36.7 192.9 442.1 679.3 1,109.6 76.2
SearD 8.0 3.9 8.8 24.9 124.6 448.9 681.4 1,499.2 64.9
WprA 2.4 2.3 5.1 25.9 153.3 471.8 927.3 1,907.7 222.6
WprB1 8.6 4.5 8.4 38.1 218.2 617.6 1,080.7 1,435.2 130.0
WprB2 5.9 3.3 7.2 31.7 152.4 312.2 525.6 1,540.4 59.7
WprB3 4.3 4.3 8.2 47.8 173.4 280.3 378.4 1,162.9 49.1
Table 4: Estimated global and regional number of total cancer deaths (thousands) and mortality rate (per 100,000) by age, males, 2000 
Region Age-group
0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total
Number of deaths (000s)
World 22.6 27.4 79.9 228.3 844.8 1,121.7 1,074.6 502.6 3,901.9
AfrD 2.1 1.3 6.2 14.3 29.2 34.2 34.8 17.1 139.3
AfrE 2.6 1.5 9.6 20.3 33.3 36.2 36.1 17.0 156.8
AmrA 0.3 0.6 2.3 10.5 54.0 74.5 105.8 77.1 325.1
AmrB 1.7 2.5 6.0 12.4 41.4 51.7 57.6 33.9 207.1
AmrD 0.4 0.8 1.4 2.2 5.4 7.5 9.6 5.9 33.3
EmrB 0.7 1.2 1.9 3.0 10.0 11.6 11.6 4.8 44.9
EmrD 1.2 1.5 2.4 5.1 9.0 8.8 7.6 2.7 38.2
EurA 0.4 0.9 3.2 15.2 90.1 151.1 205.8 127.8 594.3
EurB1 0.4 0.7 2.1 8.7 37.2 49.5 39.9 12.1 150.5
EurB2 0.1 0.3 0.8 2.0 4.4 6.6 3.9 0.7 18.9
EurC 0.4 1.0 3.3 13.8 70.1 101.2 73.5 15.9 279.2
SearB 1.5 2.0 4.2 11.8 45.4 48.4 35.7 12.8 161.8
SearD 6.0 6.0 15.5 31.0 88.4 148.3 106.4 48.7 450.1
WprA 0.1 0.2 0.8 3.4 29.2 52.8 67.0 44.9 198.5
WprB1 4.1 6.2 18.7 69.7 285.7 327.5 268.6 73.8 1,054.3
WprB2 0.5 0.6 1.6 4.6 11.4 11.7 10.3 7.2 47.9
WprB3 0.0 0.0 0.1 0.2 0.6 0.4 0.2 0.1 1.6
Age-specific mortality rate per 100,000
World 7.3 4.5 10.0 35.3 209.6 694.5 1,264.5 2,095.6 128.2
AfrD 7.6 2.9 13.5 54.6 214.0 697.7 1,607.5 3,446.7 83.9
AfrE 9.0 3.3 20.6 78.4 258.1 824.4 1,866.5 4,078.5 93.5
AmrA 3.0 2.8 7.2 28.4 190.0 689.9 1,353.3 2,286.9 213.1
AmrB 7.4 5.4 9.6 27.1 158.5 546.5 1,139.1 2,145.2 94.5
AmrD 9.0 8.9 13.5 36.2 158.0 583.7 1,505.9 3,264.8 93.6
EmrB 8.9 6.6 9.1 22.2 137.7 461.9 904.8 1,444.8 62.1
EmrD 12.9 8.9 11.8 39.2 134.5 385.5 704.1 1,014.3 54.8
EurA 3.4 3.6 7.7 31.7 230.9 762.6 1,576.8 2,711.7 295.6
EurB1 6.3 5.0 9.7 48.8 288.5 847.1 1,225.6 1,657.4 183.0
EurB2 4.8 5.6 10.9 38.8 197.1 598.0 772.0 676.4 75.0
EurC 7.0 5.6 11.6 50.4 351.0 1,001.0 1,453.4 1,541.1 242.3
SearB 7.0 4.9 7.3 28.0 199.0 569.2 905.5 1,264.7 82.0
SearD 7.1 3.8 8.0 22.7 113.7 516.9 792.8 1,419.2 64.8
WprA 2.9 2.9 5.4 22.9 181.1 668.2 1,387.3 2,603.3 270.5
WprB1 7.5 5.1 10.6 40.3 267.2 796.0 1,372.3 1,729.7 151.1
WprB2 5.9 3.8 7.6 31.3 175.1 431.4 784.9 2,303.2 68.1
WprB3 5.1 5.5 7.0 29.3 162.4 329.5 476.3 1,404.1 46.7
Table 3: Estimated global and regional number of total cancer deaths (thousands) and mortality rate (per 100,000) by age, both sexes, 
2000 (Continued)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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cause groups, including cancers. For regions with insuffi-
cient vital registration such as AFRO and SEARO regions,
this process significantly increases the mortality envelope
for these two broad cause categories. It is possible that
these methods result in an overestimate of total cancer
deaths in some regions, and continuos efforts are being
made to obtain additional data from these regions in or-
der to check the validity of these estimates, and where ap-
propriate, to improve them.
Although cancer is still a fatal disease in many developing
countries[2], there is a growing evidence that cancer sur-
vival even in developing countries is continuously im-
proving [3,4]. The present study suggests that in all
regions mortality was much higher in males while inci-
dence were almost the same due to relatively good prog-
nosis of breast and cervix cancers compared to common
cancers among males such as liver and lung cancers. Due
to the differences in survival by region, incidence-to-mor-
tality rate ratios were higher in developed in which in-
creasing disability among cancer survivors is warranted
Table 5: Estimated global and regional number of total cancer deaths (thousands) and mortality rate (per 100,000) by age, females, 
2000
Region Age-group
0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total
Number of deaths (000s)
World 23.4 22.0 61.4 233.8 658.2 730.6 826.4 576.2 3,132.0
AfrD 2.9 1.2 4.4 12.0 30.0 35.8 31.7 14.4 132.3
AfrE 2.3 1.0 5.6 12.8 31.7 40.2 35.9 14.4 144.0
AmrA 0.3 0.5 1.6 12.6 48.4 57.8 88.7 91.1 301.1
AmrB 1.5 2.0 4.7 19.3 45.0 42.6 45.9 32.7 193.8
AmrD 0.6 0.6 1.4 4.2 9.4 8.5 9.3 5.6 39.6
EmrB 0.4 0.8 1.8 5.0 9.2 6.6 6.2 2.9 32.9
EmrD 0.7 1.0 1.9 5.5 8.8 6.4 5.6 1.6 31.4
EurA 0.3 0.6 2.1 16.2 64.0 87.1 145.1 152.0 467.4
EurB1 0.3 0.4 1.8 7.9 22.1 27.1 29.9 14.4 104.0
EurB2 0.1 0.2 0.6 2.3 3.6 4.3 3.6 1.1 15.9
EurC 0.4 0.7 2.5 14.6 44.1 60.9 72.6 28.7 224.5
SearB 1.5 2.0 3.7 19.1 44.6 31.4 23.4 13.1 138.8
SearD 6.9 5.9 17.2 34.2 100.6 113.8 85.8 60.5 425.0
WprA 0.1 0.1 0.7 4.3 20.4 24.9 37.2 45.5 133.1
WprB1 4.8 4.3 9.8 58.5 165.9 175.7 198.8 91.8 709.7
WprB2 0.4 0.4 1.4 5.0 9.9 7.2 6.4 6.2 36.9
WprB3 0.0 0.0 0.1 0.4 0.6 0.3 0.2 0.1 1.7
Age-specific mortality rate per 100,000
World 8.0 3.8 8.0 37.3 163.9 414.3 737.9 1,462.6 104.6
AfrD 10.6 2.6 9.6 44.6 206.1 641.3 1,204.5 2,286.7 78.9
AfrE 8.1 2.2 12.0 48.9 230.4 777.2 1,418.8 2,202.6 84.8
AmrA 2.7 2.4 5.3 34.7 166.6 484.1 862.1 1,663.3 193.4
AmrB 6.6 4.4 7.7 40.9 161.3 392.0 705.7 1,504.1 86.9
AmrD 12.5 7.5 13.2 65.1 260.9 602.3 1,226.6 2,479.1 110.8
EmrB 5.5 4.8 9.2 42.1 151.7 280.7 474.5 909.5 49.0
EmrD 7.4 5.9 10.1 43.8 124.7 237.8 411.1 481.1 46.1
EurA 2.9 2.6 5.4 34.6 162.9 397.0 781.7 1,751.8 224.7
EurB1 5.0 3.4 8.3 45.3 166.0 394.8 632.1 1,134.8 124.4
EurB2 2.5 4.1 9.1 44.1 150.2 326.0 463.3 491.3 61.9
EurC 6.4 4.5 9.1 52.2 192.2 417.0 661.6 851.5 172.7
SearB 7.3 5.1 6.6 45.4 187.2 329.0 491.8 991.1 70.5
SearD 8.8 4.0 9.7 27.2 136.1 383.2 580.4 1,570.4 65.1
WprA 2.0 1.7 4.7 29.0 125.6 290.5 580.5 1,509.3 176.2
WprB1 9.9 3.9 6.0 35.7 165.9 435.6 839.7 1,262.3 107.6
WprB2 6.0 2.9 6.8 32.1 132.6 215.4 342.3 1,113.7 51.5
WprB3 3.5 3.0 9.5 68.4 184.5 233.3 294.1 960.7 51.7BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Table 6: Estimated global and regional number of cancer deaths and age-standardised mortality rate by site, males, 2000
WHO sub region
World AFRO AMRO EMRO EURO SEARO WPRO
Site D E A B D B D A B1 B2 C B D A B1 B2 B3
Number of deaths (000s)
Mouth and 
oropharynx 
cancers
222.4 10.7 14.3 6.6 8.5 0.7 2.0 1.5 19.2 6.0 0.8 14.7 13.1 88.9 4.1 25.5 5.4 0.4
Oesophagus 
cancer
273.6 4.9 13.8 11.6 10.5 0.7 1.8 0.7 21.4 3.4 1.7 10.0 3.3 41.9 9.4 135.7 2.9 0.0
Stomach 
cancer
512.0 12.0 9.8 10.0 25.8 7.6 7.5 2.3 38.9 14.9 3.5 42.2 7.1 28.1 34.3 261.1 6.8 0.1
Colon and 
rectum 
cancers
311.8 7.4 8.8 36.1 14.4 1.6 2.2 2.3 72.1 14.3 1.0 28.7 13.9 19.6 23.1 63.3 2.9 0.1
Liver cancer 414.9 20.6 23.5 8.7 9.3 2.8 3.0 2.3 25.3 5.8 0.7 7.8 25.9 17.3 23.8 231.5 6.3 0.2
Pancreas 
cancer
117.0 1.5 2.7 16.0 7.9 1.1 0.9 1.0 26.7 5.8 1.0 11.2 3.5 7.6 11.2 18.4 0.5 0.0
Trachea, 
bronchus, 
lung cancers
877.3 7.0 9.4 101.4 36.1 1.6 8.7 7.1 158.0 46.6 3.8 83.6 40.8 102.7 43.2 214.6 12.4 0.3
Melanoma of 
the skin
35.1 2.4 2.2 7.7 3.3 0.6 0.2 0.1 8.3 2.0 0.2 2.5 0.7 1.4 1.7 1.6 0.1 0.0
Breast cancer 2.6 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.9 0.2 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0
Cervix uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Corpus uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Ovary cancer 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Prostate 
cancer
263.6 26.0 19.2 39.6 30.4 5.8 2.1 1.7 70.2 9.4 0.5 13.3 8.1 19.8 10.4 6.1 0.9 0.0
Bladder 
cancer
123.9 6.9 4.3 10.3 4.9 0.5 2.6 7.7 27.1 7.1 0.7 10.4 4.4 15.9 4.1 15.9 1.0 0.0
Lymphomas, 
multiple 
myeloma
168.6 15.9 13.7 23.1 9.6 2.1 4.1 3.6 27.6 5.6 0.9 5.4 9.6 26.1 7.8 11.2 2.0 0.1
Leukaemia 145.3 5.2 6.9 14.5 9.6 2.0 2.3 3.7 20.0 5.4 0.8 7.8 7.6 21.0 4.9 31.9 1.7 0.1
Other 
malignant 
neoplasms
425.2 18.7 25.6 39.0 36.5 6.0 7.5 4.2 79.1 24.0 3.2 41.3 16.6 60.5 20.4 37.4 5.0 0.2
Age-standardized mortality rate per 100,000
Mouth and 
oropharynx 
cancers
7.3 11.7 16.6 2.8 4.5 2.8 4.0 3.1 5.5 5.9 4.0 9.0 8.0 16.7 2.8 3.4 10.7 18.4
Oesophagus 
cancer
9.0 5.5 16.4 4.8 5.6 3.0 3.6 1.6 5.6 3.2 9.0 5.9 2.1 7.9 6.1 18.3 6.1 1.9
Stomach 
cancer
16.8 13.5 11.7 3.9 13.7 31.5 15.1 4.9 9.3 14.2 18.7 25.1 4.5 5.3 21.5 35.5 14.2 3.3
Colon and 
rectum
 cancers
10.2 8.1 11.0 13.7 7.6 6.5 4.2 4.8 17.0 13.6 5.2 17.0 8.9 3.7 14.6 8.7 6.0 4.1
Liver cancer 13.6 20.9 25.6 3.6 4.9 11.1 6.2 5.0 6.2 5.6 3.6 4.6 15.9 3.1 15.7 30.5 12.2 10.1
Pancreas 
cancer
3.8 1.6 3.4 6.3 4.2 4.7 1.8 2.2 6.6 5.6 5.3 6.7 2.2 1.5 7.1 2.5 1.0 0.2
Trachea, 
bronchus, 
lung cancers
28.8 7.9 11.5 40.1 19.3 6.5 17.7 15.9 39.5 44.2 19.7 48.9 26.0 19.4 26.3 29.1 25.1 13.8
Melanoma of 
the skin
1.2 2.7 2.6 3.2 1.7 2.5 0.4 0.2 2.2 2.0 1.1 1.6 0.5 0.3 1.1 0.2 0.2 2.4BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Breast cancer 0.1 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.2 0.2 0.3 0.3 0.0 0.0 0.1 0.0 0.0 0.0
Cervix uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Corpus uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Ovary cancer 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Prostate 
cancer
8.7 33.3 27.9 12.7 16.2 24.9 4.5 4.3 14.3 8.8 2.9 7.8 5.6 4.1 5.7 0.9 1.9 1.5
Bladder
 cancer
4.1 8.4 5.8 3.6 2.6 2.2 5.6 17.7 6.0 6.7 4.0 6.1 2.9 3.1 2.3 2.3 2.3 0.8
Lymphomas, 
multiple 
myeloma
5.5 15.1 13.5 9.2 4.9 8.3 7.3 6.3 7.1 5.7 4.4 3.5 5.8 4.6 5.1 1.5 3.6 5.5
Leukaemia 4.8 4.9 6.7 5.9 4.7 6.5 3.7 5.9 5.4 5.7 3.4 5.3 4.2 3.3 3.9 4.6 2.6 2.6
Other 
malignant 
neoplasms
14.0 20.2 31.0 16.6 18.9 23.0 14.6 8.4 21.4 23.6 16.0 26.1 10.2 11.3 13.6 5.2 10.3 8.5
Table 7: Estimated global and regional number of cancer deaths and age-standardised mortality rate by site, females, 2000
WHO sub region
World AFRO AMRO EMRO EURO SEARO WPRO
Site D E A B D B D A B1 B2 C B D A B1 B2 B3
Number of deaths (000s)
Mouth and 
oropharynx 
cancers
97.2 5.3 7.1 3.3 2.7 0.5 1.1 0.6 5.7 1.5 0.3 2.9 5.5 42.7 1.7 13.6 2.6 0.2
Oesophagus 
cancer
157.6 4.0 6.8 3.7 3.8 0.3 1.5 0.5 7.8 1.0 1.3 3.5 2.3 33.6 2.0 83.6 2.0 0.0
Stomach 
cancer
324.2 8.9 7.2 7.0 16.5 7.1 3.7 1.6 27.9 8.6 2.2 30.6 5.5 16.1 19.0 157.7 4.6 0.1
Colon and 
rectum 
cancers
295.5 5.6 5.3 37.2 16.1 2.1 2.2 1.7 69.7 11.8 1.1 33.6
1
3.6 14.01 9.4 59.72 2.2 0.1
Liver cancer 191.0 11.0 9.8 5.3 9.1 3.2 1.2 1.1 13.3 3.8 0.5 5.6 10.6 10.4 10.5 93.5 2.2 0.2
Pancreas 
cancer
105.6 1.5 2.5 16.9 8.7 1.2 0.7 0.6 26.9 4.6 0.7 9.8 3.3 5.2 9.4 13.0 0.5 0.0
Trachea, 
bronchus, 
lung cancers
323.8 2.9 4.5 70.5 14.9 0.9 2.5 2.3 49.2 9.8 1.1 16.2 7.5 23.2 16.9 97.6 3.7 0.2
Melanoma of 
the skin
30.1 2.4 3.0 4.3 2.7 0.6 0.2 0.1 7.2 1.9 0.2 3.0 1.0 1.0 1.1 1.2 0.1 0.0
Breast cancer 466.3 18.6 23.0 53.3 30.7 4.0 5.1 7.0 91.8 18.5 2.5 39.4 29.0 67.0 12.4 57.5 6.3 0.2
Cervix uteri 
cancer
259.6 24.1 36.8 5.3 19.3 4.6 3.5 2.6 8.3 6.3 1.0 11.7 15.4 86.2 2.6 26.1 5.4 0.3
Corpus uteri 
cancer
72.9 1.4 1.7 8.2 10.4 3.5 0.4 0.3 16.0 4.3 0.8 11.0 4.0 3.2 3.3 4.1 0.2 0.0
Ovary cancer 128.6 3.9 6.7 15.5 7.0 1.1 0.9 0.9 25.7 5.7 0.6 12.9 8.7 18.5 4.9 13.8 1.6 0.1
Prostate 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bladder 
cancer
53.5 2.3 2.0 4.9 2.1 0.3 0.5 2.0 10.5 1.7 0.2 2.8 1.4 14.2 1.9 6.3 0.6 0.0
Lymphomas, 
multiple 
myeloma
163.7 6.6 5.2 21.7 8.0 1.6 2.8 2.4 27.4 4.3 0.5 4.8 6.1 54.8 6.2 9.4 1.8 0.1
Leukaemia 114.7 4.4 4.9 12.0 8.4 1.9 1.7 2.5 17.2 3.8 0.7 7.2 7.2 14.7 3.6 23.1 1.4 0.1
Table 6: Estimated global and regional number of cancer deaths and age-standardised mortality rate by site, males, 2000 (Continued)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Other 
malignant 
neoplasms
344.5 29.4 14.8 32.0 33.2 6.9 5.1 5.1 63.0 16.4 2.4 29.6 15.5 19.9 18.3 49.5 3.4 0.2
Age-standardized mortality rate per 100,000
Mouth and 
oropharynx 
cancers
3.2 6.6 8.8 1.3 1.5 2.2 2.5 1.3 1.4 1.4 1.4 1.3 3.7 9.9 1.0 2.0 4.9 10.8
Oesophagus 
cancer
5.3 5.0 8.8 1.3 2.1 1.4 3.8 1.1 1.6 0.9 6.1 1.4 1.6 7.7 1.2 12.7 3.8 1.7
Stomach 
cancer
10.8 11.3 9.2 2.5 9.1 32.2 9.0 3.6 5.8 7.9 10.6 13.0 3.7 3.8 11.5 24.1 8.7 2.6
Colon and 
rectum 
cancers
9.9 7.0 7.0 13.0 8.9 9.4 5.6 3.7 14.4 10.7 5.3 13.9 9.3 3.3 11.6 9.1 4.2 2.6
Liver cancer 6.4 12.4 11.5 2.0 5.0 13.9 3.0 2.4 2.9 3.4 2.2 2.4 7.1 2.1 6.2 13.9 3.9 6.9
Pancreas 
cancer
3.5 1.7 3.4 6.1 4.8 5.6 1.7 1.5 5.7 4.1 3.4 4.1 2.3 1.2 5.5 2.0 0.9 0.3
Trachea, 
bronchus, 
lung cancers
10.8 3.2 5.3 27.4 8.0 4.0 6.0 5.2 11.6 9.0 5.1 6.9 4.9 4.9 10.1 14.5 6.8 7.7
Melanoma of 
the skin
1.0 3.1 4.1 1.7 1.5 2.6 0.4 0.3 1.7 1.8 1.0 1.5 0.7 0.2 0.7 0.2 0.1 1.5
Breast cancer 15.6 21.4 27.7 21.1 16.0 16.1 12.2 14.4 22.8 17.4 12.0 18.7 17.6 14.5 9.4 8.1 11.3 12.0
Cervix uteri 
cancer
8.7 27.4 43.8 2.4 9.8 18.7 8.7 5.5 2.3 6.1 4.7 5.9 9.3 18.0 2.0 3.9 9.7 15.5
Corpus uteri 
cancer
2.4 1.9 2.3 3.1 5.5 1.5 1.0 0.8 3.5 3.9 3.8 4.7 2.6 0.8 2.1 0.6 0.4 1.2
Ovary cancer 4.3 4.3 8.1 6.1 3.7 4.4 2.2 1.8 6.3 5.3 3.0 6.0 5.3 4.1 3.5 2.0 2.9 3.2
Prostate 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bladder 
cancer
1.8 2.9 2.6 1.6 1.2 1.2 1.4 4.6 2.0 1.5 0.9 1.1 1.1 3.1 1.0 1.0 1.1 0.2
Lymphomas, 
multiple 
myeloma
5.5 6.7 5.6 7.9 4.2 6.5 6.3 4.8 6.1 4.1 2.4 2.3 3.9 11.7 3.8 1.4 3.0 3.1
Leukaemia 3.8 4.7 5.1 4.6 4.1 6.5 3.1 4.3 4.1 3.8 2.8 3.8 4.1 2.6 2.7 3.6 2.1 2.2
Other 
malignant 
neoplasms
11.5 34.3 18.0 12.5 17.6 28.6 12.5 10.9 14.6 15.3 11.0 14.1 10.1 4.9 11.0 7.7 6.3 8.2
Table 8: Ranking of the global cancer deaths by site, 2000
site Number of death (000s) Proportion of total (%)
Both sexes
Trachea, bronchus, and lung 1211.5 17.2
Stomach 835.1 11.9
Liver 611.4 8.7
Colon and rectum 608.0 8.6
Breast 473.8 6.7
Oesophagus 430.4 6.1
Lymphomas and myeloma 329.9 4.7
Mouth and oropharynx 320.0 4.5
Prostate 264.0 3.8
Leukaemia 263.8 3.8
Cervix uteri 254.2 3.6
Pancreas 222.3 3.2
Bladder 179.4 2.6
Ovary 130.1 1.8
Table 7: Estimated global and regional number of cancer deaths and age-standardised mortality rate by site, females, 2000 (Continued)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Corpus uteri 73.5 1.0
Melanoma of the skin 65.3 0.9
Males
Trachea, bronchus, and lung 877.2 22.5
Stomach 511.3 13.1
Liver 419.4 10.7
Colon and rectum 312.3 8.0
Oesophagus 272.8 7.0
Prostate 264.0 6.8
Mouth and oropharynx 222.0 5.7
Lymphomas and myeloma 169.6 4.3
Leukaemia 145.4 3.7
Bladder 126.1 3.2
Pancreas 116.8 3.0
Melanoma of the skin 35.0 0.9
Females
Breast 471.2 15.0
Trachea, bronchus, and lung 334.2 10.7
Stomach 323.7 10.3
Colon and rectum 295.7 9.4
Cervix uteri 254.2 8.1
Liver 192.1 6.1
Lymphomas and myeloma 160.2 5.1
Oesophagus 157.6 5.0
Ovary 130.1 4.2
Leukaemia 118.4 3.8
Pancreas 105.5 3.4
Mouth and oropharynx 98.0 3.1
Corpus uteri 73.5 2.3
Bladder 53.4 1.7
Melanoma of the skin 30.3 1.0
Table 9: Ranking of selected regional cancer deaths by site, 2000
WHO sub region
AfrE (high child and adult mortality) EurA (very low child and adult mortality) SearB (low child and adult mortality)
site Number of 
death (000s)
Proportion 
of total (%)
site Number of 
death (000s)
Proportion 
death of 
total (%)
site Number of 
death (000s)
Proportion 
death of 
total (%)
Both sexes
Cervix uteri 37.3 12.4 Trachea, bron-
chus, and lung
207.1 19.5 Trachea, bron-
chus, and lung
48.3 16.1
Liver 35.3 11.7 Colon and rectum 141.6 13.3 Liver 39.4 13.1
Breast 23.8 7.9 Breast 92.7 8.7 Breast 29.4 9.8
Mouth and 
oropharynx
21.6 7.2 Prostate 70.1 6.6 Colon and 
rectum
28.5 9.5
Oesophagus 20.7 6.9 Stomach 66.7 6.3 Mouth and 
oropharynx
19.4 6.5
Lymphomas and 
myeloma
19.2 6.4 Lymphomas and 
myeloma
55.0 5.2 Lymphomas and 
myeloma
16.2 5.4
Prostate 19.2 6.4 Pancreas 53.6 5.0 Cervix uteri 15.6 5.2
Stomach 17.1 5.7 Liver 38.5 3.6 Leukaemia 15.1 5.0
Colon and 
rectum
14.3 4.8 Bladder 37.6 3.5 Stomach 13.1 4.3
Table 8: Ranking of the global cancer deaths by site, 2000 (Continued)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Trachea, bron-
chus, and lung
14.0 4.6 Leukaemia 37.2 3.5 Ovary 8.8 2.9
Leukaemia 12.4 4.1 Oesophagus 29.2 2.7 Prostate 8.5 2.8
Ovary 6.9 2.3 Ovary 25.7 2.4 Pancreas 7.0 2.3
Bladder 6.3 2.1 Mouth and 
oropharynx
24.9 2.3 Bladder 6.2 2.1
Melanoma of 
the skin
5.3 1.8 Corpus uteri 16.0 1.5 Oesophagus 5.9 2.0
Pancreas 5.3 1.8 Melanoma of the 
skin
15.5 1.5 Corpus uteri 4.1 1.4
Corpus uteri 1.7 0.6 Cervix uteri 8.3 0.8 Melanoma of 
the skin
1.8 0.6
Males
Liver 24.9 15.9 Trachea, bron-
chus, and lung
158.0 26.6 Trachea, bron-
chus, and lung
40.8 25.2
Prostate 19.2 12.2 Colon and rectum 72.0 12.1 Liver 28.4 17.6
Mouth and 
oropharynx
14.4 9.2 Prostate 70.1 11.8 Colon and 
rectum
14.6 9.1
Lymphomas and 
myeloma
14.0 8.9 Stomach 38.8 6.5 Mouth and 
oropharynx
13.8 8.5
Oesophagus 13.8 8.8 Lymphomas and 
myeloma
27.6 4.6 Lymphomas and 
myeloma
10.0 6.2
Stomach 9.9 6.3 Bladder 27.1 4.6 Prostate 8.5 5.3
Trachea, bron-
chus, and lung
9.4 6.0 Pancreas 26.7 4.5 Leukaemia 7.8 4.8
Colon and 
rectum
9.0 5.7 Liver 25.3 4.3 Stomach 7.5 4.6
Leukaemia 7.3 4.7 Oesophagus 21.4 3.6 Bladder 4.7 2.9
Bladder 4.3 2.7 Leukaemia 20.0 3.4 Pancreas 3.6 2.2
Pancreas 2.8 1.8 Mouth and 
oropharynx
19.2 3.2 Oesophagus 3.6 2.2
Melanoma of 
the skin
2.3 1.4 Melanoma of the 
skin
8.3 1.4 Melanoma of 
the skin
0.7 0.5
Females
Cervix uteri 37.3 25.9 Breast 91.8 19.6 Breast 29.3 21.1
Breast 23.8 16.5 Colon and rectum 69.6 14.9 Cervix uteri 15.6 11.3
Liver 10.3 7.2 Trachea, bron-
chus, and lung
49.2 10.5 Colon and 
rectum
13.9 10.0
Stomach 7.2 5.0 Stomach 27.8 6.0 Liver 11.0 7.9
Mouth and 
oropharynx
7.2 5.0 Lymphomas and 
myeloma
27.4 5.9 Ovary 8.8 6.3
Ovary 6.9 4.8 Pancreas 26.9 5.8 Trachea, bron-
chus, and lung
7.5 5.4
Oesophagus 6.8 4.8 Ovary 25.7 5.5 Leukaemia 7.2 5.2
Colon and 
rectum
5.3 3.7 Leukaemia 17.2 3.7 Lymphomas and 
myeloma
6.2 4.5
Lymphomas and 
myeloma
5.3 3.7 Corpus uteri 16.0 3.4 Mouth and 
oropharynx
5.6 4.0
Leukaemia 5.1 3.5 Liver 13.3 2.8 Stomach 5.6 4.0
Trachea, bron-
chus, and lung
4.5 3.2 Bladder 10.5 2.2 Corpus uteri 4.1 2.9
Melanoma of 
the skin
3.0 2.1 Cervix uteri 8.3 1.8 Pancreas 3.4 2.4
Pancreas 2.5 1.8 Oesophagus 7.8 1.7 Oesophagus 2.4 1.7
Bladder 2.0 1.4 Melanoma of the 
skin
7.2 1.5 Bladder 1.5 1.1
Corpus uteri 1.7 1.2 Mouth and 
oropharynx
5.7 1.2 Melanoma of 
the skin
1.0 0.7
Table 9: Ranking of selected regional cancer deaths by site, 2000 (Continued)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Table 10: Estimated global site-specific cancer incidence-to-mortality rate ratios by sex
Site Male Female
Mouth and oropharynx 1.20 1.57
Oesophagus 1.05 1.05
Stomach 1.15 1.19
Colon and rectum 1.69 1.75
Liver 1.01 1.06
Pancreas 1.02 1.01
Trachea, bronchus, and lung 1.07 1.10
Melanoma of the skin 3.37 2.93
Breast 2.19
Cervix uteri 1.91
Corpus uteri 4.45
Ovary 1.70
Prostate 2.08
Bladder 2.21 2.01
Lymphomas and multiple myeloma 1.40 1.51
Leukaemia 1.35 1.44
Other malignant neoplasms 1.49 1.63
Table 11: Estimated global and regional number of new cases (thousands) and incidence rate (per 100,000) of all cancers by age, both 
sexes, 2000
Age group
Region 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total
Number of new cases (000s)
World 136.8 96.5 360.1 923.3 2459.3 2641.4 2514.5 1160.2 10292.1
AfrD 12.5 4.6 24.7 41.9 87.6 90.8 74.5 31.9 368.6
AfrE 12.8 4.9 33.8 49.1 99.2 102.4 81.0 31.9 415.1
AmrA 3.0 3.3 22.7 110.4 306.3 308.4 404.2 176.4 1334.8
AmrB 10.0 8.5 31.5 76.1 150.8 137.5 127.6 69.2 611.1
AmrD 2.9 2.6 7.5 15.6 28.5 23.8 22.7 11.9 115.5
EmrB 3.5 4.3 8.8 15.7 28.4 24.0 20.5 7.9 113.2
EmrD 5.4 4.7 9.3 20.0 28.2 19.9 15.1 4.4 106.9
EurA 2.7 3.6 23.8 96.6 323.0 421.1 531.4 322.2 1724.3
EurB1 2.1 2.2 11.0 33.8 91.6 105.0 84.4 27.1 357.2
EurB2 0.6 1.2 3.7 8.4 11.7 14.0 8.7 1.9 50.2
EurC 2.6 3.5 18.0 60.8 172.9 222.9 180.5 46.1 707.3
SearB 8.8 7.5 18.9 65.1 138.9 103.9 67.6 26.7 437.5
SearD 39.6 24.2 85.1 111.0 277.0 317.7 208.4 110.8 1173.9
WprA 0.9 0.9 6.8 25.7 108.2 133.0 153.0 107.7 536.1
WprB1 26.9 18.3 47.7 176.3 575.8 593.2 516.0 170.3 2124.4
WprB2 2.5 2.0 6.6 15.6 29.5 22.9 18.2 13.6 110.8
WprB3 0.1 0.1 0.4 1.2 1.9 0.9 0.5 0.2 5.2
Age-specific incidence rate per 100,000
World 22.6 8.1 23.0 72.4 305.6 781.8 1276.6 1830.7 170.4
AfrD 22.9 5.2 26.8 78.9 310.4 866.4 1554.9 2834.8 110.4
AfrE 22.3 5.2 36.3 94.3 371.8 1070.3 1812.2 2975.0 123.0
AmrA 14.4 7.5 36.4 150.7 532.9 1356.3 2232.0 1994.7 433.0
AmrB 21.9 9.5 25.4 82.0 279.1 676.3 1103.7 1842.4 138.2
AmrD 30.8 15.1 36.5 123.3 406.3 881.5 1623.0 2921.2 162.0
EmrB 21.4 12.3 21.4 62.2 213.6 494.3 793.5 1206.4 81.1
EmrD 28.9 14.2 23.8 78.2 205.5 401.7 619.9 728.7 77.5
EurA 12.4 7.5 29.6 102.1 412.5 1008.3 1681.0 2406.4 421.6BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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EurB1 17.0 8.5 25.3 95.7 349.8 826.0 1056.8 1355.2 215.4
EurB2 10.5 9.7 26.6 81.0 254.7 577.3 674.1 560.0 98.7
EurC 20.6 10.3 32.4 109.7 403.0 901.9 1125.9 1048.5 288.5
SearB 21.4 9.3 16.8 77.4 297.8 575.8 776.5 1142.3 110.9
SearD 24.4 7.9 22.9 42.4 182.7 544.1 738.9 1521.0 87.1
WprA 10.9 5.8 22.1 86.1 334.2 808.6 1361.9 2273.3 360.0
WprB1 26.1 7.8 14.0 52.3 278.2 728.1 1193.0 1475.8 156.5
WprB2 16.6 6.3 15.8 51.7 210.3 378.2 572.8 1565.2 78.0
WprB3 11.7 7.7 21.6 93.3 271.0 364.6 422.9 1174.1 76.4
Table 12: Estimated global and regional number of new cases (thousands) and incidence rate (per 100,000) of all cancers by age, males, 
2000
Age group
Region 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total
Number of new cases (000s)
World 64.5 50.9 154.0 257.7 1174.2 1528.4 1380.8 556.5 5167.1
AfrD 5.2 2.3 10.4 13.0 37.9 45.1 39.0 17.3 170.2
AfrE 6.6 2.8 15.3 18.3 42.5 47.2 40.0 17.2 189.9
AmrA 1.6 1.7 11.0 28.3 134.7 174.3 226.6 109.9 688.2
AmrB 5.3 4.4 13.9 15.7 56.1 70.5 68.2 34.6 268.7
AmrD 1.2 1.4 2.8 2.6 7.2 10.5 11.2 6.0 42.9
EmrB 2.2 2.5 3.6 3.4 13.2 14.7 13.1 4.9 57.5
EmrD 3.4 2.7 4.3 6.3 13.3 11.5 8.5 2.7 52.8
EurA 1.5 2.0 11.5 26.4 153.8 250.2 291.4 139.6 876.3
EurB1 1.1 1.3 4.8 10.8 49.4 63.2 45.7 12.2 188.5
EurB2 0.4 0.7 1.6 2.2 5.3 7.9 4.3 0.7 23.1
EurC 1.4 1.8 8.1 17.5 90.3 126.3 84.3 16.0 345.6
SearB 4.3 3.3 7.0 11.8 57.2 59.7 39.5 13.0 195.8
SearD 16.2 11.8 27.0 29.8 110.2 173.8 113.7 49.1 531.6
WprA 0.5 0.5 3.0 5.8 51.0 86.0 94.3 51.3 292.3
WprB1 12.3 10.5 27.1 61.4 337.9 373.6 289.8 74.8 1187.5
WprB2 1.2 1.0 2.5 4.2 13.5 13.5 11.0 7.2 54.2
WprB3 0.1 0.1 0.1 0.2 0.7 0.5 0.3 0.1 2.0
Age-specific incidence rate per 100,000
World 20.8 8.3 19.2 39.8 291.3 946.2 1624.8 2320.5 169.7
AfrD 18.7 5.2 22.6 49.5 277.5 921.0 1801.5 3472.3 102.4
AfrE 23.1 5.9 32.8 70.5 328.9 1075.5 2067.8 4109.5 113.2
AmrA 15.3 7.6 34.8 76.6 474.1 1614.6 2897.4 3261.5 451.0
AmrB 22.6 9.6 22.4 34.4 215.1 745.8 1347.6 2190.5 122.6
AmrD 25.6 16.0 27.0 42.0 212.4 814.8 1742.9 3320.7 120.7
EmrB 26.0 13.8 17.2 25.2 181.4 584.4 1018.0 1464.3 79.6
EmrD 36.1 16.2 21.6 48.4 199.2 503.8 791.2 1024.4 75.6
EurA 13.3 8.2 27.9 55.2 394.2 1262.9 2233.2 2960.3 435.9
EurB1 18.5 9.5 21.8 60.5 383.2 1081.9 1403.2 1668.1 229.1
EurB2 13.5 10.6 22.9 43.2 238.3 710.9 851.6 678.2 91.7
EurC 21.4 10.7 28.7 63.8 451.9 1248.4 1667.0 1551.3 299.9
SearB 20.3 8.0 12.3 28.1 250.5 702.6 1001.8 1284.1 99.2
SearD 19.4 7.5 14.0 21.8 141.7 606.1 847.2 1430.6 76.5
WprA 12.8 6.7 18.9 38.6 316.3 1088.7 1953.2 2971.8 398.4
WprB1 22.7 8.6 15.4 35.5 316.0 908.2 1480.4 1753.4 170.2
WprB2 15.4 6.6 11.6 28.6 207.3 500.1 835.9 2327.7 77.2
WprB3 13.5 9.0 10.5 27.9 214.4 400.7 515.2 1412.7 57.5
Table 11: Estimated global and regional number of new cases (thousands) and incidence rate (per 100,000) of all cancers by age, both 
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[17–19]. It is suggested that data on incidence as well as
mortality are necessary to understand the magnitude and
trends of cancer problems and to evaluate the interven-
tions against cancer in the context of prevention [1].
When setting priorities, interventions against cancers need
to be compared with other health interventions which
aims at reducing only morbidity [5,20].
GBD 2000 employs a composite measure of disease bur-
den in terms of disability-adjusted life years (DALYs)
which consist of years lived with disability (morbidity)
and years of life lost (mortality) [5]. As a part of this exer-
cise, we have estimated both mortality and incidence of
cancers by site. We will further estimate the years lived
with disability to derive cancer burden in DALYs once
weights assigned to disabling conditions are revised based
on the estimates from the on-going population-based sur-
veys from more than 70 countries [21].
The presents study also suggests that there is a significant
variation in the distribution of cancer mortality and inci-
dence by region depending on age and population struc-
Table 13: Estimated global and regional number of new cases (thousands) and incidence rate (per 100,000) of all cancers by age, females, 
2000
Age group
Region 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total
Number of new cases (000s)
World 72.3 45.6 206.1 665.6 1285.1 1112.9 1133.6 603.7 5125.0
AfrD 7.4 2.3 14.2 28.9 49.6 45.8 35.6 14.7 198.4
AfrE 6.1 2.1 18.5 30.8 56.7 55.1 41.0 14.8 225.2
AmrA 1.4 1.6 11.7 82.1 171.6 134.2 177.7 66.5 646.7
AmrB 4.7 4.1 17.5 60.4 94.7 66.9 59.5 34.6 342.4
AmrD 1.7 1.2 4.7 13.0 21.3 13.3 11.5 5.9 72.6
EmrB 1.3 1.8 5.2 12.4 15.2 9.3 7.4 3.0 55.6
EmrD 1.9 2.0 5.0 13.7 14.9 8.4 6.6 1.7 54.1
EurA 1.2 1.6 12.3 70.2 169.2 170.9 240.0 182.7 848.0
EurB1 0.9 0.9 6.2 23.0 42.2 41.8 38.7 14.9 168.8
EurB2 0.2 0.5 2.1 6.2 6.4 6.1 4.4 1.2 27.1
EurC 1.2 1.6 9.9 43.3 82.7 96.7 96.2 30.2 361.7
SearB 4.5 4.2 11.9 53.3 81.7 44.2 28.1 13.7 241.7
SearD 23.4 12.4 58.1 81.2 166.8 143.8 94.7 61.7 642.2
WprA 0.3 0.4 3.8 19.9 57.2 47.1 58.7 56.4 243.8
WprB1 14.6 7.8 20.6 114.8 237.8 219.6 226.2 95.5 936.9
WprB2 1.3 0.9 4.1 11.4 15.9 9.3 7.2 6.3 56.5
WprB3 0.0 0.1 0.3 1.0 1.1 0.4 0.2 0.1 3.2
Age-specific incidence rate per 100,000
World 24.6 7.9 27.0 106.1 320.0 631.1 1012.3 1532.5 171.1
AfrD 27.2 5.1 30.9 107.8 341.2 818.6 1352.1 2330.7 118.3
AfrE 21.6 4.6 39.8 117.9 412.0 1065.8 1616.9 2253.0 132.6
AmrA 13.5 7.4 38.1 226.2 590.3 1123.0 1726.5 1214.7 415.3
AmrB 21.2 9.3 28.4 127.8 339.0 615.8 914.1 1589.7 153.5
AmrD 36.2 14.2 46.1 200.8 588.6 942.4 1521.8 2602.4 203.0
EmrB 16.6 10.7 25.8 104.3 252.3 397.3 571.2 937.3 82.8
EmrD 21.5 12.1 26.1 109.2 211.4 315.0 484.3 495.4 79.3
EurA 11.5 6.8 31.5 150.3 430.7 778.6 1292.8 2105.4 407.8
EurB1 15.4 7.4 29.0 131.6 317.4 608.6 818.5 1175.8 202.0
EurB2 7.5 8.8 30.4 117.2 270.0 464.6 559.4 504.5 105.5
EurC 19.7 9.9 36.1 154.6 360.5 661.9 876.5 895.0 278.3
SearB 22.5 10.8 21.3 126.4 343.1 463.0 589.7 1033.9 122.7
SearD 29.8 8.3 32.6 64.8 225.9 484.2 640.6 1601.5 98.4
WprA 9.0 4.9 25.5 134.4 351.9 550.0 916.0 1873.2 322.7
WprB1 29.8 7.0 12.5 70.1 237.8 544.5 955.4 1312.9 142.1
WprB2 17.9 6.1 20.2 73.7 212.9 279.2 386.9 1138.6 78.8
WprB3 9.6 6.3 33.4 166.5 328.3 330.2 343.6 973.9 96.5BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Table 14: Estimated global and regional number of new cases and age-standardised incidence rate of cancer by site, males, 
2000
WHO sub region
World AFRO AMRO EMRO EURO SEARO WPRO
Site D E A B D B D A B1 B2 C B D A B1 B2 B3
Number of new cases (000s)
Mouth and 
oropharynx 
cancers
267.1 12.1 16.5 11.3 10.4 0.9 2.6 1.7 28.7 7.4 0.9 17.8 16.0 98.1 6.5 29.7 6.1 0.5
Oesophagus 
cancer
286.5 5.1 14.1 12.4 11.1 0.7 1.9 0.8 22.8 3.6 1.8 10.7 3.8 42.0 10.1 142.7 3.0 0.0
Stomach 
cancer
589.3 13.3 10.9 11.8 29.7 8.7 8.6 2.5 45.6 17.2 4.0 48.6 8.6 30.1 40.6 300.9 7.6 0.1
Colon and 
rectum 
cancers
527.8 9.5 12.0 85.6 21.2 2.2 3.2 3.1 133.8 21.5 1.4 42.8 21.4 25.7 49.2 91.0 3.8 0.1
Liver cancer 422.0 20.0 23.6 9.0 9.5 2.9 3.1 2.3 26.1 6.0 0.7 7.9 28.6 18.4 24.6 232.8 6.2 0.2
Pancreas 
cancer
119.3 1.5 2.8 16.5 8.1 1.2 0.9 1.0 27.4 5.9 1.0 11.4 3.7 7.3 11.5 18.7 0.5 0.0
Trachea, 
bronchus, 
lung cancers
939.9 7.4 9.8 112.1 38.5 1.7 9.3 7.4 172.0 49.5 3.9 89.3 43.1 107.8 46.9 227.8 13.1 0.3
Melanoma of 
the skin
118.2 3.5 3.4 61.8 5.3 0.9 0.3 0.2 22.6 3.2 0.3 4.0 1.2 2.1 6.7 2.6 0.1 0.1
Breast 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cervix uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Corpus uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Ovary cancer 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Prostate 
cancer
550.2 36.5 28.2 165.7 46.0 8.6 3.2 2.7 139.1 15.2 0.8 22.3 13.4 29.6 28.1 9.5 1.2 0.0
Bladder 
cancer
277.2 10.6 7.3 60.3 8.1 0.8 4.1 14.4 65.1 12.1 1.2 17.8 7.7 27.8 13.5 24.8 1.5 0.0
Lymphomas, 
multiple 
myeloma
238.5 20.3 18.6 36.2 13.4 2.8 6.5 5.2 39.3 7.8 1.3 7.4 13.3 36.5 11.8 15.2 2.6 0.2
Leukaemia 195.2 6.3 9.2 20.6 13.1 2.9 3.4 5.3 25.6 6.6 1.1 9.3 10.7 28.2 6.7 44.0 2.2 0.1
Other 
malignant 
neoplasms
635.8 24.2 33.5 84.8 54.2 8.6 10.3 6.2 128.4 32.5 4.7 56.3 24.2 77.8 35.8 47.7 6.4 0.3
Age-standardised incidence rate per 100,000
Mouth and 
oropharynx 
cancers
8.8 12.9 18.4 5.0 5.5 3.3 4.9 3.6 8.6 7.4 4.5 10.9 9.3 18.5 4.7 3.9 12.0 21.7
Oesophagus 
cancer
9.4 5.7 16.8 5.1 5.9 3.1 3.8 1.7 6.0 3.4 9.4 6.3 2.2 8.2 6.6 19.2 6.3 2.0
Stomach 
cancer
19.4 15.0 13.0 4.6 15.8 35.8 17.4 5.5 11.0 16.4 21.3 28.8 5.2 5.9 25.6 40.8 15.9 3.8
Colon and 
rectum 
cancers
17.3 10.4 14.6 34.4 11.3 9.2 6.3 6.5 33.0 20.4 7.1 25.1 12.9 4.9 32.4 12.3 7.8 5.8
Liver cancer 13.7 20.3 24.7 3.7 5.0 11.4 6.4 5.0 6.4 5.7 3.6 4.8 16.0 3.2 16.2 30.8 12.1 9.9
Pancreas 
cancer
3.9 1.6 3.5 6.5 4.3 4.8 1.8 2.3 6.8 5.7 5.3 6.8 2.2 1.5 7.3 2.5 1.0 0.2
Trachea, 
bronchus, 
lung cancers
30.9 8.3 12.0 44.8 20.6 6.9 18.9 16.6 43.3 47.1 20.6 52.2 27.5 20.3 28.9 30.8 26.4 14.7
Melanoma of 
the skin
3.9 3.8 3.7 27.2 2.8 3.7 0.6 0.3 6.6 3.1 1.6 2.6 0.7 0.4 4.9 0.3 0.3 3.6BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/37
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Breast 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cervix uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Corpus uteri 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Ovary cancer 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Prostate 
cancer
18.0 45.0 38.9 63.7 24.8 36.3 6.9 6.5 31.8 14.1 4.4 12.8 8.6 5.8 17.1 1.3 2.5 2.3
Bladder 
cancer
9.0 12.0 8.8 24.4 4.3 3.3 8.5 30.5 16.1 11.6 6.4 10.7 4.6 4.8 8.7 3.5 3.1 1.4
Lymphomas, 
multiple 
myeloma
7.8 18.2 17.0 15.3 6.8 10.7 10.6 8.6 10.9 8.1 6.2 5.1 7.6 6.1 8.2 2.1 4.5 7.1
Leukaemia 6.4 5.5 7.7 8.9 6.3 8.6 5.1 7.8 7.5 7.2 4.3 6.8 5.7 4.3 5.8 6.7 3.3 3.3
Other 
malignant 
neoplasms
20.8 24.1 37.1 39.9 27.2 31.0 19.1 11.3 39.1 32.8 22.4 37.5 13.5 13.7 27.0 6.6 12.4 11.2
Table 15: Estimated global and regional number of new cases and age-standardised incidence rate of cancer by site, females, 
2000
WHO sub region
World AFRO AMRO EMRO EURO SEARO WPRO
Site D E A B D B D A B1 B2 C B D A B1 B2 B3
Number of new cases (000s)
Mouth and 
oropharynx 
cancers
153.6 8.2 11.4 5.9 4.6 0.8 2.2 1.1 9.9 2.5 0.5 4.6 9.4 63.6 3.0 21.2 4.2 0.4
Oesophagus 
cancer
166.2 4.2 7.2 3.3 4.0 0.3 1.6 0.5 8.4 1.0 1.3 3.8 2.5 34.9 2.1 89.0 2.0 0.0
Stomach 
cancer
383.9 10.3 8.4 7.1 19.7 8.4 4.5 2.0 33.9 10.2 2.6 36.3 6.7 18.1 23.7 186.7 5.1 0.1
Colon and 
rectum 
cancers
517.3 8.5 8.2 73.8 26.2 3.3 4.0 2.8 131.0 19.0 1.8 54.1 22.8 21.1 41.7 95.5 3.3 0.1
Liver cancer 204.4 11.9 11.1 4.7 9.7 3.4 1.3 1.2 14.0 4.0 0.5 5.9 11.7 12.0 11.1 99.6 2.2 0.2
Pancreas 
cancer
106.9 1.6 2.6 14.3 9.1 1.3 0.8 0.7 28.1 4.8 0.7 10.2 3.6 5.3 9.8 13.6 0.5 0.0
Trachea, 
bronchus, 
lung cancers
365.7 3.1 5.0 74.6 16.4 1.0 3.0 2.6 55.3 10.8 1.1 17.7 8.3 25.9 18.9 117.7 4.0 0.2
Melanoma of 
the skin
88.5 3.3 4.3 26.5 5.7 0.9 0.4 0.3 26.5 3.5 0.3 5.9 1.9 1.7 5.0 2.2 0.1 0.1
Breast 
cancer
1031.9 28.3 39.8 226.5 59.3 7.2 10.2 13.6 221.8 32.6 4.5 68.5 53.9 109.0 43.7 102.1 10.2 0.5
Cervix uteri 
cancer
487.5 43.3 67.9 16.1 40.6 9.2 6.7 5.6 18.8 12.6 1.9 22.5 32.8 146.7 6.6 45.0 10.2 0.8
Corpus uteri 
cancer
326.3 4.6 6.0 46.0 48.8 8.6 1.6 1.3 68.3 17.9 3.8 43.6 19.9 11.7 17.3 17.4 0.8 0.1
Ovary 
cancer
221.3 7.1 12.2 22.4 13.2 2.1 2.1 2.0 39.4 10.0 1.2 21.6 18.1 31.9 8.4 26.6 2.9 0.2
Prostate 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bladder 
cancer
105.7 3.6 3.4 14.9 3.5 0.4 0.8 3.7 21.4 2.7 0.3 4.4 2.4 28.9 4.6 9.7 1.0 0.0
Table 14: Estimated global and regional number of new cases and age-standardised incidence rate of cancer by site, males, 
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Lymphomas, 
multiple 
myeloma
242.6 10.2 8.0 32.2 12.4 2.3 5.0 4.0 40.9 6.9 1.0 7.3 9.6 74.9 9.7 15.2 2.7 0.1
Leukaemia 169.5 5.9 7.0 14.7 12.4 2.9 2.6 3.8 23.0 4.9 0.9 9.0 10.8 24.9 5.2 39.4 1.9 0.1
Other malig-
nant neo-
plasms
553.9 44.2 22.7 63.6 56.7 11.7 8.9 8.9 107.3 25.3 4.4 46.5 27.3 31.7 32.7 56.1 5.3 0.3
Age-standardised incidence rate per 100,000
Mouth and 
oropharynx 
cancers
5.1 9.2 12.6 2.6 2.4 3.4 4.6 2.2 2.7 2.5 2.5 2.2 5.7 13.5 2.2 3.1 7.7 18.6
Oesophagus 
cancer
5.6 5.2 9.2 1.3 2.2 1.5 4.0 1.1 1.8 1.0 6.5 1.5 1.7 8.0 1.3 13.4 3.9 1.8
Stomach 
cancer
12.8 12.7 10.5 2.9 10.7 37.4 10.9 4.3 7.3 9.4 12.4 15.6 4.4 4.3 14.9 28.2 10.1 3.1
Colon and 
rectum 
cancers
17.3 9.9 10.2 29.8 14.1 14.4 9.4 5.9 29.2 17.2 8.6 23.0 14.7 4.7 26.7 14.2 6.3 4.2
Liver cancer 6.8 13.0 12.0 1.9 5.2 14.6 3.1 2.5 3.1 3.6 2.3 2.5 7.5 2.3 6.6 14.8 4.2 7.6
Pancreas 
cancer
3.6 1.8 3.5 5.6 5.0 5.8 1.9 1.6 6.0 4.3 3.6 4.3 2.4 1.3 5.8 2.1 0.9 0.4
Trachea, 
bronchus, 
lung cancers
11.9 3.5 5.8 30.5 8.8 4.4 6.7 5.6 13.4 9.9 5.5 7.6 5.4 5.3 11.6 16.0 7.4 8.4
Melanoma of 
the skin
2.9 3.9 5.3 12.6 2.9 4.0 0.8 0.6 7.9 3.4 1.4 3.2 1.2 0.3 4.2 0.3 0.2 2.8
Breast 
cancer
34.2 29.9 41.6 103.5 29.7 27.6 22.5 26.2 64.1 32.0 21.2 35.4 30.7 20.9 38.6 14.1 18.5 21.9
Cervix uteri 
cancer
16.6 43.3 69.8 8.2 19.8 34.9 15.0 10.7 6.2 12.8 9.0 12.7 18.4 30.2 6.0 6.6 18.0 33.1
Corpus uteri 
cancer
10.8 5.2 6.8 20.3 24.5 32.8 3.7 2.8 18.4 17.1 18.1 21.2 11.5 2.1 13.3 2.4 1.5 5.2
Ovary 
cancer
7.3 6.8 12.1 9.8 6.6 7.9 4.3 3.7 10.8 9.9 5.6 11.2 10.2 6.2 6.8 3.6 5.0 6.3
Prostate 
cancer
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bladder 
cancer
3.6 4.1 3.9 6.0 1.9 1.8 2.2 7.9 4.6 2.4 1.5 1.9 1.6 5.7 2.7 1.5 1.8 0.6
Lymphomas, 
multiple 
myeloma
8.3 9.1 7.7 13.8 6.3 9.2 9.9 7.2 10.6 7.0 4.4 4.0 5.8 15.7 6.7 2.2 4.4 4.8
Leukaemia 5.5 5.6 6.1 6.6 6.0 9.1 4.3 5.9 6.0 5.2 3.8 5.2 6.0 3.9 4.4 5.8 3.0 2.9
Other 
malignant 
neoplasms
18.8 45.9 24.0 30.2 28.6 44.0 20.0 17.2 29.6 24.9 19.6 25.8 16.1 6.1 23.3 10.7 9.4 129
Table 16: Ranking of the global cancer incidence by site, 2000
site Number of death (000s) Proportion of total (%)
Both sexes
Trachea, bronchus, and lung 1305.6 12.7
Stomach 1045.0 10.2
Liver 1031.9 10.0
Colon and rectum 973.1 9.5
Breast 626.4 6.1
Oesophagus 550.2 5.3
Lymphomas and myeloma 487.5 4.7
Mouth and oropharynx 481.1 4.7
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Prostate 452.7 4.4
Leukaemia 420.7 4.1
Cervix uteri 382.9 3.7
Pancreas 364.7 3.5
Bladder 326.3 3.2
Ovary 226.2 2.2
Corpus uteri 221.3 2.2
Melanoma of the skin 206.7 2.0
Males
Trachea, bronchus, and lung 939.9 18.2
Stomach 589.3 11.4
Liver 550.2 10.6
Colon and rectum 527.8 10.2
Oesophagus 422.0 8.2
Prostate 286.5 5.5
Mouth and oropharynx 277.2 5.4
Lymphomas and myeloma 267.1 5.2
Leukaemia 238.5 4.6
Bladder 195.2 3.8
Pancreas 119.3 2.3
Melanoma of the skin 118.2 2.3
Females
Breast 1031.9 20.1
Trachea, bronchus, and lung 517.3 10.1
Stomach 487.5 9.5
Colon and rectum 383.9 7.5
Cervix uteri 365.7 7.1
Liver 326.3 6.4
Lymphomas and myeloma 242.6 4.7
Oesophagus 221.3 4.3
Ovary 204.4 4.0
Leukaemia 169.5 3.3
Pancreas 166.2 3.2
Mouth and oropharynx 153.6 3.0
Corpus uteri 106.9 2.1
Bladder 105.7 2.1
Melanoma of the skin 88.5 1.7
Table 17: Ranking of the selected regional cancer incidence by site, 2000
WHO sub region
AfrE (high child and adult mortality) EurA (very low child and adult mortality) SearB (low child and adult mortality)
site Number of Proportion site Number of Proportion site Number of Proportion
(000s) (%) (000s) (%) (000s) (%)
Both sexes
Cervix uteri 67.9 16.4 Trachea, 
bronchus, and 
lung
264.7 15.4 Trachea, 
bronchus, and 
lung
53.9 12.3
Liver 39.8 9.6 Colon and 
rectum
227.3 13.2 Liver 51.4 11.7
Breast 34.7 8.3 Breast 221.8 12.9 Breast 44.3 10.1
Mouth and 
oropharynx
28.2 6.8 Prostate 139.1 8.1 Colon and 
rectum
40.3 9.2
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Oesophagus 27.9 6.7 Stomach 86.5 5.0 Mouth and 
oropharynx
32.8 7.5
Lymphomas 
and myeloma
26.6 6.4 Lymphomas 
and myeloma
80.2 4.7 Lymphomas 
and myeloma
25.4 5.8
Prostate 21.2 5.1 Pancreas 79.6 4.6 Cervix uteri 22.9 5.2
Stomach 20.3 4.9 Liver 68.3 4.0 Leukaemia 21.5 4.9
Colon and 
rectum
19.4 4.7 Bladder 55.5 3.2 Stomach 19.9 4.5
Trachea, 
bronchus, and 
lung
16.2 3.9 Leukaemia 49.1 2.8 Ovary 18.1 4.1
Leukaemia 14.8 3.6 Oesophagus 48.6 2.8 Prostate 15.3 3.5
Ovary 12.2 2.9 Ovary 40.1 2.3 Pancreas 13.4 3.1
Bladder 10.7 2.6 Mouth and 
oropharynx
39.4 2.3 Bladder 10.1 2.3
Melanoma of 
the skin
7.7 1.8 Corpus uteri 38.6 2.2 Oesophagus 7.2 1.7
Pancreas 6.0 1.4 Melanoma of 
the skin
31.2 1.8 Corpus uteri 6.2 1.4
Corpus uteri 5.4 1.3 Cervix uteri 18.8 1.1 Melanoma of 
the skin
3.1 0.7
Males
Liver 28.2 14.8 Trachea, 
bronchus, and 
lung
172.0 19.6 Trachea, 
bronchus, and 
lung
43.1 22.0
Prostate 23.6 12.4 Colon and 
rectum
139.1 15.9 Liver 28.6 14.6
Mouth and 
oropharynx
18.6 9.8 Prostate 133.8 15.3 Colon and 
rectum
21.4 11.0
Lymphomas 
and myeloma
16.5 8.7 Stomach 65.1 7.4 Mouth and 
oropharynx
16.0 8.2
Oesophagus 14.1 7.4 Lymphomas 
and myeloma
45.6 5.2 Lymphomas 
and myeloma
13.4 6.9
Stomach 12.0 6.3 Bladder 39.3 4.5 Prostate 13.3 6.8
Trachea, 
bronchus, and 
lung
10.9 5.8 Pancreas 28.7 3.3 Leukaemia 10.7 5.5
Colon and 
rectum
9.8 5.2 Liver 27.4 3.1 Stomach 8.6 4.4
Leukaemia 9.2 4.9 Oesophagus 26.1 3.0 Bladder 7.7 3.9
Bladder 7.3 3.8 Leukaemia 25.6 2.9 Pancreas 3.8 1.9
Pancreas 3.4 1.8 Mouth and 
oropharynx
22.8 2.6 Oesophagus 3.7 1.9
Melanoma of 
the skin
2.8 1.5 Melanoma of 
the skin
22.6 2.6 Melanoma of 
the skin
1.2 0.6
Females
Cervix uteri 67.9 30.2 Breast 221.8 26.2 Breast 53.9 22.3
Breast 39.8 17.7 Colon and 
rectum
131.0 15.4 Cervix uteri 32.8 13.6
Liver 12.2 5.4 Trachea, 
bronchus, and 
lung
68.3 8.1 Colon and 
rectum
22.8 9.4
Stomach 11.4 5.1 Stomach 55.3 6.5 Liver 19.9 8.2
Mouth and 
oropharynx
11.1 4.9 Lymphomas 
and myeloma
40.9 4.8 Ovary 18.1 7.5
Ovary 8.4 3.7 Pancreas 39.4 4.6 Trachea, 
bronchus, and 
lung
11.7 4.8
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ture, distribution of risk factors, and opportunity of
detection and treatment [2,22]. However, the frequent
cancers such as lung, liver and cervical cancers are poten-
tially preventable [23]. For example, Parkin has estimated
that there would have been 23% fewer cases of cancers in
the developing world in 1990, if infections such as hepa-
titis B and C virus and human papilloma virus had been
prevented [24]. Another estimate suggests that 230,000
deaths (more than 4% of all cancer deaths) from liver can-
cer could have been avoided with only immunisations
against hepatitis B [13]. Smoking was estimated to be re-
sponsible for another 20% of all cancer deaths, all of
which are preventable [13].
Given a high incidence of cancers which are potentially
preventable in both developed and developing countries,
the role of primary prevention, early detection as well as
treatment should be evaluated more carefully [2]. Cost-ef-
fectiveness analysis plays a role for this purpose, which
should be generalisable and comparable across various in-
terventions including both currently delivered and poten-
tially feasible ones [20]. Estimating the magnitude of
cancer mortality and incidence is a key input for setting re-
search and intervention priorities. Combined with costs
of each intervention, mortality and incidence estimates
provide a basis for effectiveness calculation in cost-effec-
tiveness analysis of cancer control programmes.
Conclusions
Based on the algorithm to estimate region-specific overall
cancer mortality, and site-specific survival, death distribu-
tions, and incidence as a part of GBD 2000 study, it is es-
timated that cancers accounted for over 7 million deaths
(13% of total mortality) and more than 10 million new
cases occurred world wide in 2000. Cancer mortality and
incidence in developing countries already accounted for
over 60% and about half of the global total, respectively.
Although there was a significant variation in the distribu-
tion of cancer mortality and incidence by region, many of
the common cancers are potentially preventable. Magni-
tude of cancer burden estimation by taking into account
both mortality and morbidity is an essential information
to set research priorities and policy formulation and can
be used for setting cancer control priorities when com-
bined with data on costs of interventions.
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